Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $91.30

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been given a consensus rating of “Buy” by the eight analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $91.30.

A number of equities analysts have commented on RARE shares. StockNews.com started coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, October 5th. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 1st. Cantor Fitzgerald restated an “overweight” rating and set a $114.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 25th. Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Finally, Piper Sandler cut their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a report on Wednesday, October 25th.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 970 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $37.15, for a total value of $36,035.50. Following the sale, the chief accounting officer now directly owns 23,777 shares of the company’s stock, valued at approximately $883,315.55. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Erik Harris sold 6,000 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $37.96, for a total value of $227,760.00. Following the sale, the executive vice president now directly owns 51,281 shares of the company’s stock, valued at approximately $1,946,626.76. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 970 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $37.15, for a total transaction of $36,035.50. Following the sale, the chief accounting officer now directly owns 23,777 shares in the company, valued at $883,315.55. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,864 shares of company stock valued at $3,263,279. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently modified their holdings of the company. Truist Financial Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 31.7% during the 2nd quarter. Truist Financial Corp now owns 19,613 shares of the biopharmaceutical company’s stock worth $905,000 after purchasing an additional 4,726 shares during the last quarter. Privium Fund Management B.V. boosted its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the 2nd quarter. Privium Fund Management B.V. now owns 112,241 shares of the biopharmaceutical company’s stock worth $5,236,000 after purchasing an additional 1,500 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ultragenyx Pharmaceutical by 33.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 951 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 239 shares during the last quarter. DNB Asset Management AS acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $546,000. Finally, Pictet Asset Management SA boosted its stake in shares of Ultragenyx Pharmaceutical by 314.6% during the 1st quarter. Pictet Asset Management SA now owns 334,033 shares of the biopharmaceutical company’s stock worth $13,395,000 after purchasing an additional 253,463 shares during the last quarter. 96.37% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock opened at $39.97 on Friday. Ultragenyx Pharmaceutical has a one year low of $31.52 and a one year high of $54.98. The firm has a fifty day moving average of $36.06 and a two-hundred day moving average of $41.53.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.